Everolimus clinical trials
Also written RAD001, Afinitor and Certican.
Related medicines add 2 studies
Counted the way a researcher would: Everolimus with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Everolimus is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Everolimus studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 30 Mar 2009 · AFINITOR · NDA 022334 (FDA, Drugs@FDA)
- European Union
- 2 Aug 2009 · Afinitor · EMEA/H/C/001038 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
614 studies that test it; most in 2009 (70)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 14 |
| 2005 | 27 |
| 2006 | 33 |
| 2007 | 31 |
| 2008 | 57 |
| 2009 | 70 |
| 2010 | 66 |
| 2011 | 50 |
| 2012 | 51 |
| 2013 | 36 |
| 2014 | 38 |
| 2015 | 24 |
| 2016 | 21 |
| 2017 | 18 |
| 2018 | 7 |
| 2019 | 9 |
| 2020 | 6 |
| 2021 | 5 |
| 2022 | 7 |
| 2023 | 8 |
| 2024 | 12 |
| 2025 | 7 |
| 2026 | 11 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 130 · Other 486
Novartis Pharmaceuticals (112) · M.D. Anderson Cancer Center (30) · Dana-Farber Cancer Institute (15) · Memorial Sloan Kettering Cancer Center (14) · Emory University (11) · Fudan University (9) · Mayo Clinic (9) · SCRI Development Innovations, LLC (9)
Often tested with
Tested in the same studies.
Tacrolimus (18) · Letrozole (13) · Sorafenib (13) · Bevacizumab (13) · Mycophenolic Acid (12) · Pazopanib (9) · Paclitaxel (9) · Capecitabine (9)
Related medicines
As reviewed, each with the page that says it.
- One of Immunosuppressive Agents source
- One of mTOR inhibitors source
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 9 phase 3 studies under way
Everolimus is the comparator. A study of two new drugs counts under both.
- 2177Lu-octreotide, DOTA(0)-Tyr(3)- · ITM Solucin GmbH, Grupo Espanol de Tumores Neuroendocrinos · next primary completion Mar 2029
- 1Belzutifan · Merck Sharp & Dohme LLC
- 1Actinium AC-225 dotatate · RayzeBio, Inc. · next primary completion Dec 2026
- 1Zanzalintinib · Exelixis · next primary completion Jun 2029
- 1Dordaviprone · Gustave Roussy, Cancer Campus, Grand Paris · next primary completion Sep 2028
- 1HRS-8080 · Shandong Suncadia Medicine Co., Ltd. · next primary completion Aug 2027
- 1Sirolimus · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · next primary completion Aug 2028
Reaching primary completion within a year · 16, 3 in phase 3
Studies that test Everolimus, phase 3 first.
- Feb 2027Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentPhase 3 · Novartis Pharmaceuticals
- Jul 2027A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.Phase 3 · Pfizer
- Sep 2027Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.Phase 3 · MedSIR
- Dec 2026Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)Phase 2 · Fox Chase Cancer Center
- Dec 2026RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDSPhase 1 · Richard Stone, MD
- Dec 2026The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory EpilepsyEarly Phase 1 · Xuanwu Hospital, Beijing
- Dec 2026Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung CancerPhase 1 · M.D. Anderson Cancer Center
- Dec 2026Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)Phase 1/2 · Second Affiliated Hospital, School of Medicine, Zhejiang University
- Mar 2027Phase I/II Trial of Everolimus in Combination With Lonafarnib in ProgeriaPhase 1/2 · Boston Children's Hospital
- Mar 2027Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver CancerPhase 4 · Baylor Research Institute
Studies
Open first, then newest update. How each study uses Everolimus is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 616
- Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma: a Phase 2 Study.RecruitingPhase 2Kidney Cancer Research BureauNCT07937553Written as everolimus
- Expanding Liver Transplant Immunosuppression Minimization Via EverolimusRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT06280950Written as Everolimus
- Pilot Trial for Treatment of Recurrent GlioblastomaEnrolling by invitationEarly Phase 1AHS Cancer Control AlbertaNCT05432518Written as Everolimus
- Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated RejectionRecruitingNot applicableHospices Civils de LyonNCT03955172Written as Everolimus
- A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.RecruitingPhase 3PfizerNCT07062965Written as Everolimus
- Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION)RecruitingPhase 3Hannover Medical SchoolNCT07739914Written as Everolimus
- Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.RecruitingPhase 3MedSIRNCT06382948Written as Everolimus
- Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)RecruitingPhase 1University of California, San FranciscoNCT04485559Written as Everolimus
- Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent SarcomaRecruitingNot applicableM.D. Anderson Cancer CenterNCT04199026Written as Everolimus
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135Written as Everolimus
- Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial CancerRecruitingPhase 1M.D. Anderson Cancer CenterNCT07318324Written as Everolimus
- Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical TrialRecruitingPhase 2Central Hospital, Nancy, FranceNCT06126588Written as Everolimus
- Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial CancerNot yet recruitingPhase 2Jonsson Comprehensive Cancer CenterNCT07634601Written as Everolimus
- Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline MutationsNot yet recruitingPhase 2/3Boston Children's HospitalNCT07218575Written as Everolimus blinded oral capsules
- RESTOR: PK/PD mTORi Inhibition in Older AdultsRecruitingEarly Phase 1The University of Texas Health Science Center at San AntonioNCT06658093Written as Everolimus
- Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutantRecruitingPhase 2Nationwide Children's HospitalNCT05843253Written as Everolimus
- Rapalog Pharmacology (RAP PAC) StudyRecruitingPhase 1University of Wisconsin, MadisonNCT05949658Written as Everolimus
- HORUS-Cytomegalovirus Open Proof-of-concept Exploratory TrialNot yet recruitingPhase 4Oriol ManuelNCT07570433Written as Switch from MPA to a mammalian target of rapamycin inhibitor (mTORi), together with an adapted dose of tacrolimus
- The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory EpilepsyRecruitingEarly Phase 1Xuanwu Hospital, BeijingNCT07095933Written as Everolimus
- EVR and EPO for Liver Transplant ToleranceRecruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT06832189Written as Everolimus
See all 616 studies that test Everolimus →
Given beside what is tested · 105 — Everolimus is usual care or a partner of the new treatment
- KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast CancerNot yet recruitingPhase 2Beijing Konruns Pharmaceutical Co., Ltd.NCT07937605Written as Everolimus (10 mg QD)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT04802759Written as Everolimus
- A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.RecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07900516Written as Everolimus (Afinitor®)
- Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 MedulloblastomaNot yet recruitingPhase 1Bożenna Dembowska BagińskaNCT07865130Written as Everolimus (Afinitor) tablets
- Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic MalignancyRecruitingPhase 4Dana-Farber Cancer InstituteNCT07426484Written as Everolimus
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentRecruitingPhase 2Centre Leon BerardNCT02029001Written as Everolimus (10 mg QD)
- Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerRecruitingPhase 1/2Ellipses PharmaNCT05573126Written as Everolimus
- FUSCC Refractory TNBC Platform Study (FUTURE2.0)RecruitingPhase 2Fudan UniversityNCT05749588Written as E2: SHR-A1811 with everolimus
- A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BCRecruitingPhase 1/2Forward Pharmaceuticals Co., Ltd.NCT07002177Written as Everolimus 10 mg
- Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular CarcinomaNot yet recruitingPhase 1Captor Therapeutics S.A.NCT06994572Written as EVEROLIMUS
- Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerRecruitingPhase 2West China HospitalNCT06482086Written as Everolimus
- Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.Not yet recruitingPhase 1/2Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06682611Written as Everolimus
- Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast CancerRecruitingPhase 2Fudan UniversityNCT05949541Written as Everolimus 10 mg
- A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)Active, not recruitingPhase 3Genentech, Inc.NCT05306340Written as Everolimus
- Phase I Trial of VS-6766 Alone and in Combination With EverolimusCompletedPhase 1Royal Marsden NHS Foundation TrustNCT02407509Written as Everolimus
- Treg Modulation With CD28 and IL-6 Receptor AntagonistsCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT04066114Written as everolimus
- Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerActive, not recruitingPhase 1Olema Pharmaceuticals, Inc.NCT05508906Written as Everolimus
- Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALLActive, not recruitingPhase 1Dana-Farber Cancer InstituteNCT03740334Written as Everolimus
- Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.Active, not recruitingPhase 1AstraZenecaNCT03616587Written as AZD9833 with everolimus
- A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)Active, not recruitingPhase 3Jiangsu Simcere Pharmaceutical Co., Ltd.NCT06680921Written as Everolimus (Afinitor®)
Showing 20 of 105.
As the comparator · 30 — what is tested is compared with Everolimus
- Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05773274Written as Everolimus
- Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine TumorsRecruitingPhase 2National Cancer Institute (NCI)NCT04665739Written as Everolimus
- Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsRecruitingPhase 2/3ExelixisNCT06943755Written as Everolimus
- Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0RecruitingPhase 3Gustave Roussy, Cancer Campus, Grand ParisNCT05476939Written as Everolimus
- A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast CancerRecruitingPhase 3Shandong Suncadia Medicine Co., Ltd.NCT07024173Written as Everolimus Tablets
- MTOR Inhibitors in Older AdultsRecruitingPhase 1/2University of Texas Southwestern Medical CenterNCT06727305Written as Everolimus 0.5 MG Oral Tablet
- EVERolimus and LenvAtinib Versus Everolimus for Bone SarcomaNot yet recruitingPhase 2Yonsei UniversityNCT07619950Written as Everolimus
- Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.RecruitingPhase 3Grupo Espanol de Tumores NeuroendocrinosNCT05918302Written as Everolimus
- Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine TumorsRecruitingPhase 2/3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT07165886Written as Everolimus
- A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT04195750Written as Everolimus
- Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET PatientsActive, not recruitingPhase 3ITM Solucin GmbHNCT03049189Written as Everolimus
- Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)CompletedPhase 2/3HutchmedNCT05522231Written as axitinib / everolimus
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyActive, not recruitingPhase 3RayzeBio, Inc.NCT05477576Written as Everolimus
- Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT06428396Written as Everolimus
- A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of TreatmentActive, not recruitingPhase 2PfizerNCT06105632Written as Everolimus
- Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSEActive, not recruitingPhase 3ITM Solucin GmbHNCT04919226Written as Everolimus
- A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast CancerCompletedPhase 2Queen Mary University of LondonNCT02216786Written as Everolimus
- De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised StudyWithdrawnPhase 3Rennes University HospitalNCT02909335Written as Everolimus
- Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)CompletedPhase 3Bristol-Myers SquibbNCT01668784Written as Everolimus
- MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell CarcinomaCompletedPhase 2Millennium Pharmaceuticals, Inc.NCT02724020Written as Everolimus
Showing 20 of 30.
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
Codes
What other systems call Everolimus · ClinicalTrials.gg INT006510
- MeSH (NLM) D000068338EverolimusConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 9HW64Q8G6GEVEROLIMUSConfirmed FDA, NLM, Wikidata
- RxNorm 141704Confirmed FDA, Wikidata
- Wikidata Q421052everolimusConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C48387EverolimusOne source FDA
- DrugBank DB01590One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068338 | Everolimus | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 9HW64Q8G6G | EVEROLIMUS | Confirmed FDA, NLM, Wikidata |
| RxNorm | 141704 | — | Confirmed FDA, Wikidata |
| Wikidata | Q421052 | everolimus | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C48387 | Everolimus | One source FDA |
| DrugBank | DB01590 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.